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Abstract
Introduction Nebivolol, a highly selective b1-adrenergic
receptor-blocker, increases basal and stimulated endo-
thelial nitric oxide (NO)-release. It is unknown, whether
coronary perfusion is improved by the increase in NO
availability. Therefore, we sought to evaluate the effect
of nebivolol on coronary flow reserve (CFR) and
collateral flow.
Methods Doppler-flow wire derived coronary flow
velocity measurements were obtained in ten controls
and eight patients with coronary artery disease (CAD)
at rest and after intracoronary nebivolol. CFR was
defined as maximal flow during adenosine-induced
hyperemia divided by resting flow. In the CAD group,
collateral flow was determined after dilatation of a
flow-limiting coronary stenosis. Collateral flow index
(CFI) was defined as the ratio of flow velocity during
balloon inflation divided by resting flow.
Results CFR at rest was 3.0T0.6 in controls and 2.1T0.4
in CAD patients. After intracoronary doses of 0.1,
0.25, and 0.5 mg nebivolol, CFR increased to 3.4T0.7,
3.9T0.9, and 4.0T0.1 (p<0.01) in controls, and to 2.3T0.7,
2.6T0.9, and 2.6T0.5 (p<0.05) in CAD patients. CFI
decreased significantly with intracoronary nebivolol
and correlated to changes in heart rate (r=0.75,
p<0.001) and rate-pressure product (r=0.59, p=0.001).
Discussion Intracoronary nebivolol is associated with
a significant increase in CFR due to reduction in resting
flow (controls), or due to an increase in maximal
coronary flow (CAD patients). CFI decreased with
nebivolol parallel to the reduction in myocardial
oxygen consumption.
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Introduction
The phenomenon of hypoxemia-induced increase in
coronary flow was first described by Hilton and
Eicholtz in 1925 [1]. Their findings were confirmed
by Katz and Lindner in 1939 who reported a quanti-
tative relation between reactive hyperemia and myo-
cardial ischemia [2]. However, it was not until 1960
that the concept of coronary flow reserve was intro-
duced by Coffman and Gregg [3] to assess the capacity
of coronary circulation to conduct maximal hyperemic
blood flow. Subsequently, coronary flow reserve has
been used as a clinical parameter for assessing the
functional significance of intermediate coronary ste-
noses. Three types of stimuli have been used to elicit
maximal coronary blood flow in humans: (1) transient
coronary occlusion during angioplasty (reactive hyper-
emia) [4]; (2) pharmacologic agents such as papaverine
[5–7], adenosine [6–8], and dipyridamole [8]; (3)
dynamic exercise [9].
Coronary flow reserve is defined as the ratio of
coronary blood flow during maximal vasodilatation di-
vided by resting flow, and measures the ability of the
two components of myocardial perfusion, namely,
epicardial stenosis resistance and microvascular resis-
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tance, to achieve maximal blood flow. In the absence of
epicardial coronary artery lesions, the pressure–flow
relationship is linear and steep during maximal vasodi-
latation and, therefore, peak flow is a function of
coronary resistance [10]. Therapeutic interventions
may affect coronary flow reserve by changing resting
or maximal flow. A small increase in resting flow leads,
however, to a large decrease in coronary flow reserve,
and vice versa.
Beta-blockers reduce oxygen consumption of the
myocardium and thus, diminish myocardial ischemia
(=reduced demand). In addition, metoprolol has
been shown to improve myocardial perfusion [11,
12] by increasing coronary flow reserve (=increased
supply). This effect was mainly due to an increase
in hyperemic flow rather than a decrease in
resting flow. Nebivolol, a highly selective b1-adren-
ergic receptor-blocker with nitric oxide-modulating
properties [13], might be especially useful for im-
proving coronary flow reserve due to its vasodilating
properties on the small and large coronary arteries.
Thus, the purpose of the present study was to
evaluate the effect of intracoronary nebivolol on
coronary flow velocity reserve and coronary flow
reserve in controls and in patients with coronary
artery disease using adenosine as stimulus for
maximal flow increase. In addition, the effect of
intracoronary nebivolol on collateral flow was
assessed in patients with coronary artery disease
during balloon inflation by calculating the collateral
flow index.
Methods
Patient population Ten patients with angiographically
normal coronary arteries (controls) and eight patients
with one-vessel and one-lesion coronary artery disease
(coronary artery disease group) were included in the
present analysis (Table 1). Exclusion criteria were:
untreated hypertension, know allergy or intolerance to
beta-blocking agents, alcohol or drug abuse, renal
insufficiency, clinically significant extracardiac disease,
as well as diffuse or two and three vessel coronary
artery disease. Diagnostic coronary angiography and
left heart catheterization were performed with stan-
dard techniques. Aortic and left ventricular pressures
were measured with a pigtail catheter. Biplane left
ventricular angiography was performed at the end of
diagnostic coronary angiography.
Stent implantation Of the eight coronary artery disease
patients, three had an RCA lesion (two segment 2 and
one segment 3), two an LAD lesion (both segment 13)
and two an LCX lesion (both segment 20). Stent
implantation was performed according to standard
technique. Only bare-metal stents were implanted.
Three patients received a BX-SONICi stent (Cordis),
three patients an AVEi stent (Medtronic), and two
patients a Visioni (Guidant) stent. Lesion length was
8.1T2.1 mm, preprocedure minimal lumen diameter was
0.57T0.45 mm, mean stent length was 14T5 mm, nominal
stent diameter 3.0T0.2 mm and acute gain in-stent was
2.53T0.34 mm.
Table 1 Patient characteristics
Controls (%) n CAD (%) p value
Number of patients 10 – 8
Age (year) 57T6 – 55T10 0.68
Men 7 (70) 6 (75) 0.81
Smoking 3 (30) 6 (75) 0.06
Diabetes mellitus 2 (20) 1 (12.5) 0.67
Family history of CAD 4 (40) 4 (50) 0.67
Hypertension 6 (60) 3 (37.5) 0.34
Hypercholesterolemia 7 (70) 7 (87.5) 0.38
Cholesterol (mmol/l) 5.1T0.6 5.2T0.6 0.8
LVEDP (mmHg) 11T3 10T2 0.58
LV-EF (%) 63T7 60T6 0.67
Aspirin 7 (70) 8 (100) 0.09
Betablockers (metoprolol) 5 (50) 5 (62.5) 0.6
Calcium antagonists 1 (10) 1 (12.5) 0.87
Lipid lowering agents 7 (70) 6 (75) 0.81
ACE inhibitors 5 (50) 8 (100) 0.02
Nitrates 1 (10) 3 (37.5) 0.16
LVEDP Left ventricular end-diastolic pressure; LV-EF left ventricular ejection fraction; CAD coronary artery disease
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Doppler-flow velocity measurements Doppler-flow ve-
locity was measured with a 0.014 in. Doppler-guide
wire with a 12-MHz piezoelectric crystal at its tip
(FloWire\, Volcano Therapeutics Inc., Rancho Cor-
dova, CA, USA). The validation of this Doppler-guide
wire has been described previously [14]. In coronary
artery disease patients, the tip of the Doppler guide-
wire was placed distal to the stent. Coronary flow
velocity reserve was calculated from hyperemic peak
flow velocity averaged over two cardiac cycles (aver-
aged peak velocity=APV, cm/sec) divided by resting
flow velocity. Pharmacologic modulation of coronary
flow velocity reserve was induced by an intracoronary
bolus of 18 mg adenosine for the left and 12 mg for the
right coronary artery, respectively [7]. Coronary vas-
cular resistance was calculated from mean aortic
pressure divided by mean coronary flow velocity
(mmHgsec/cm). Coronary resistance ratio was calcu-
lated from coronary resistance during hyperemia
divided by resistance at rest. Coronary flow was
calculated from coronary flow velocity multiplied by
cross-sectional area of the artery at the tip of the flow
wire measured by quantitative coronary angiography
using the ACA package of Philips DC/Integris system.
Flow data were normalized by a factor of 0.5 assuming
a parabolic flow profile and by a factor of 0.6
converting cm/sec into ml/min [14]. From these mea-
surements coronary flow reserve was determined. In
patients with coronary artery disease, after treatment
of a flow-limiting stenosis with stent implantation,
collateral flow velocity was calculated during subse-
quent balloon inflations. The collateral flow index
(CFI) was determined as the ratio of the flow velocity
time integral distal to the occluded artery during
balloon inflation divided by baseline flow velocity
obtained at the same location prior to balloon inflation.
Study protocol
1. Baseline: Vasoactive medication (including beta-
blockers) was discontinued at least 48 h before cath-
eterization. After coronary angiography and stent
implantation for clinical purpose (only in coronary
artery disease group), an interval of at least 15 min was
allowed for dissipation of the effect of nonionic
contrast medium. Two hundred micrograms of nitro-
glycerin was administered intracoronary for maximal
vasodilation. Heart-rate, mean aortic pressure as well
as coronary cross-sectional area at the tip of the flow
wire were determined in all patients. Baseline coro-
nary flow velocity and flow measurements were
performed. Intracoronary adenosine was administered
for assessment of coronary flow velocity and flow
reserve, followed by a 1 min balloon inflation within
stented segment (only in coronary artery disease
group) for calculation of collateral flow index (Fig. 1).
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Fig. 1 Study protocol: After coronary angiography and stent
implantation (only in CAD group), an interval of at least 15 min
was allowed for dissipation of the effect of nonionic contrast
medium. Two hundred micrograms of nitroglycerin was admin-
istered i.c. for maximal vasodilation. Baseline coronary flow
velocity and flow measurements were performed. Intracoronary
adenosine (ADN) was administered for assessment of coronary
flow velocity and flow reserve (CFR), followed by a 1 min balloon
inflation within stented segment (only in CAD group) for
calculation of collateral flow index (CFI). Three intracoronary
nebivolol infusions were performed over a period of 5 min with
increasing doses (0.1, 0.25, and, 0.5 mg) separated by intervals of
10 min to allow coronary flow reach baseline level. At the end of
each infusion period ADN was administered for CFR calculation
followed by a 1 min balloon inflation (only in CAD group) for
CFI calculation. Asterisk = procedures and measurements
performed only in CAD group
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2. Infusion of intracoronary nebivolol: Three intracoro-
nary nebivolol infusions were administered over 5 min
with increasing doses (0.1, 0.25, and, 0.5 mg/min)
separated by intervals of 10 min to allow coronary
flow reach baseline level. These doses adhere to
comparable intra-arterial infusions into the brachial
artery reported previously [15]. Doppler flow veloci-
ties were measured continuously. At the end of each
infusion period, hyperemia was induced with adeno-
sine for calculation of coronary flow and flow velocity
reserve, followed by a 1 min balloon inflation (only in
coronary artery disease group) for coronary flow
index calculation (Fig. 2).
Ethics
The study protocol was approved by the local ethics
committee, and written informed consent was obtained
from all patients.
Statistical analysis
Comparison of angiographic, hemodymamic, and
Doppler-flow velocity data was performed by an
unpaired Student t-test (continuous variables ) and by
a c2-test (categorical variables). A two-way analysis of
variance for repeated measurements was performed
for comparison of hemodynamic and Doppler-flow
data during nebivolol administration. Multivariable
logistic regression analysis was performed to deter-
mine the effect of cardiovascular risk factors (hyper-
tension, smoking) and baseline medication (ACE
inhibitors and nitrates) as covariates on coronary flow
velocity and coronary flow (including coronary flow
velocity reserve and coronary flow reserve) response
to nebivolol application. Correlation between coronary
flow index and heart rate as well as rate-pressure
product was performed using the square method. The
correlation coefficient (r) and the regression equation
were calculated from these data. Statistical significance
was defined at a p value of <0.05.
Results
Baseline patient characteristics Patients in the two
groups were well matched with regard to age, gender,
presence of risk factors (diabetes mellitus, family
history, and hypercholesterolemia) as well as medica-
tion (beta-blockers, calcium-antagonists). There was
an imbalance with regard to history of smoking (higher
incidence of smokers in the coronary artery disease
group, p=0.06) and medication with ACE inhibitors
(all coronary artery disease patients on ACE-inhibitor
medication as opposed to only 50% in the control
group, p=0.02) (Table 1).
Hemodynamics There was a significant decrease in
heart rate after nebivolol administration in both
groups. Mean aortic pressure remained unchanged
after nebivolol in controls as well as in coronary
Fig. 2 Representative recordings of coronary flow velocity in a
coronary artery disease patient before (left) and after 0.5 mg
intracoronary nebivolol (right). Coronary flow velocity at rest
remained unchanged (from 16 to 15 cm/sec after 0.5 mg nebivolol),
whereas maximal flow velocity increased from 49 to 58 cm/sec,
respectively. As a consequence, coronary flow velocity reserve
increased from 3.1 to 3.8
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artery disease patients. As a consequence, the rate-
pressure product (RPP) decreased after intracoronary
nebivolol from 10.4103 to 8.9103 mmHg/min
(p<0.05) in controls and from 9.9103 to 8.5103
mmHg/min (p<0.05) in coronary artery disease patients
(Table 2).
Coronary flow velocity and flow reserve Coronary flow
velocity reserve at rest was 3T0.6 in controls and 2.1T0.4
in coronary artery disease patients (p<0.05). Coronary
flow velocity reserve increased after intracoronary
doses of 0.1, 0.25 and 0.5 mg nebivolol to 3.1T0.6
(ns), 3.5T0.8 (p<0.05), 3.6T0.8 (p<0.05) in controls and
Table 2 Hemodynamics
Baseline Nebivolol 0.1 mg Nebivolol 0.25 mg Nebivolol 0.5 mg
Controls:
HR (beats/min) 73T16 68T15 66T14** 64T11**
Systolic blood pressure (mmHg) 142T15 143T14 140T11 139T11
Diastolic blood pressure (mmHg) 82T8 83T9 80T8 81T7
RPP (mmHg103/min) 10.4 9.7 9.2 8.9*
CAD group:
HR (beats/min) 71T9 70T11 65T7* 63T9*
Systolic blood pressure (mmHg) 140T21 140T26 135T17 135T16
Diastolic blood pressure (mmHg) 84T10 82T11 75T13 76T14
RPP (mmHg103/min) 9.9 9.8 8.8* 8.5*
HR Heart rate; RPP rate-pressure product
*p<0.05, **p<0.01
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Fig. 3 Box plot of coronary flow reserve (CFR) at rest and after
intracoronary nebivolol in controls (left panel) and in CAD
patients (right panel). CFR increased after intracoronary doses of
0.1, 0.25, and 0.5 mg nebivolol from 3.0T0.6 to 3.4T0.7 (p<0.05),
3.9T0.9 (p<0.01) and 4.0T0.1 (p<0.01) in controls and from
2.1T0.4 to 2.3T0.7 (ns), 2.6T0.9 (ns), and 2.6T0.5 (p<0.05) in CAD
patients, respectively (abbreviations as in Fig. 1)
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to 2.2T0.7, 2.5T1.0, 2.4T0.6 (all ns) in coronary artery
disease patients, respectively. The similar pattern was
observed for coronary flow reserve in both groups.
Precisely, coronary flow reserve at rest was 3.0T0.6 in
controls and 2.1T0.4 in coronary artery disease patients
(p<0.05). Coronary flow reserve increased after intra-
coronary doses of 0.1, 0.25, and 0.5 mg nebivolol to
3.4T0.7 (p<0.05), 3.9T0.9 (p<0.01), and 4.0T0.1 (p<0.01)
in controls, and to 2.3T0.7 (ns), 2.6T0.9 (ns), and 2.6T0.5
(p<0.05) in coronary artery disease patients, respec-
tively (Fig. 3) (Tables 3 and 4).
Coronary vascular resistance Coronary vascular resis-
tance (CR) at rest increased after nebivolol in controls,
whereas it did not change in coronary artery disease
patients. Hyperemic coronary vascular resistance
remained unchanged after nebivolol in controls, where-
as it decreased significantly after 0.25 mg (p<0.05) and
0.5 mg (p<0.05) intracoronary nebivolol in coronary
artery disease patients. Coronary resistance ratio at rest
was 0.34T0.8 in controls and 0.5T0.1 in coronary artery
disease patients, and decreased with 0.5 mg nebivolol
to 0.29T0.6 in controls (p<0.01) and to 0.45T0.1 (ns) in
coronary artery disease patients, respectively (Table 5).
Collateral flow index Coronary flow index decreased
from 0.37T0.23 to 0.33T0.25, 0.28T0.3 (p<0.05), and
0.27T0.30 (p<0.05), respectively after 0.1, 0.25, and 0.5
mg intracoronary nebivolol. There was a significant
correlation between heart-rate and coronary flow
index (r=0.76, p<0.0001), as well as between rate-
pressure product and coronary flow index (r=0.59,
p<0.001), respectively (Figs. 4 and 5).
Discussion
The present study shows that: (1) Intracoronary
nebivolol is associated with a significant increase in
both coronary flow velocity reserve and coronary flow
reserve in patients with angiographically normal coro-
nary arteries due to a reduction in resting but no
change in maximal flow. (2) In coronary artery disease
patients, coronary flow velocity reserve and coronary
flow reserve increase after nebivolol due to an increase
in maximal but no change in resting coronary flow. (3)
Collateral flow decreases after nebivolol due to the
reduction in myocardial oxygen requirements.
Table 3 Coronary flow velocity
Baseline Nebivolol 0.1 mg Nebivolol 0.25 mg Nebivolol 0.5 mg
Controls:
CFV rest (cm/sec) 18T2 16T2 15T2* 14T2**
CFV hyperemic(cm/sec) 54T8 50T7 50T7 49T7
CFVR 3T0.6 3.1T0.6 3.5T0.8* 3.6T0.8*
CSA (mm2) 5.1T1.9 5.0T1.8 5.0T1.8 5.0T1.7
Coronary artery disease group:
CFV rest (cm/sec) 24T7 25T7 26T7 24T8
CFV hyperemic (cm/sec) 49T17 54T13 61T20 56T13
CFVR 2.1T0.4 2.2T0.7 2.5T1 2.4T0.6
CSA (mm2) 5.0T1.4 5.3T1.4 5.1T1.4 5.2T1.3
CFV Coronary flow velocity; CFVR coronary flow velocity reserve; CSA cross sectional area
sec*p<0.05; **p<0.01
Table 4 Coronary flow
Baseline Nebivolol 0.1 mg Nebivolol 0.25 mg Nebivolol 0.5 mg
Controls:
CFR 3T0.6 3.4T0.7* 3.9T0.9** 4.0T1**
CF rest (ml/sec) 113T31 126T45 121T30 111T24
CF hyperemic(ml/sec) 239T83 276T78 297T79 277T54*
Coronary artery disease group:
CFR 2.1T0.4 2.3T0.7 2.6T0.9 2.6T0.5*
CF rest (ml/sec) 83T35 74T29 68T30* 63T27**
CF hyperemic (ml/sec) 236T80 240T81 244T84 236T80
CF Coronary flow; CFR coronary flow reserve
*p<0.05; **p<0.01
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Changes in coronary hemodynamics associated with
the administration of b-blockers have been extensively
studied in the past [16]. Previous clinical studies using
coronary flow measurements suggest that non-selective
b-adrenergic antagonists are associated with an increase
in coronary vascular resistance during hyperemia and,
therefore, reduce coronary flow reserve [17, 18]. This
phenomenon has been attributed to the unopposed
alpha-adrenergic vasomotor tone. Selective b-adrener-
gic antagonists on the other hand are associated with an
increase of coronary flow reserve [11]. The increase in
coronary flow reserve with metoprolol administration
is achieved by an increase in maximal coronary flow
which is further enhanced by a decrease in resting flow
[11, 12]. With metoprolol, coronary vascular resistance
decreases during adenosine-induced hyperemia.
Nebivolol combines potent b1-adrenoreceptor-
blocking activity with nitric oxide-mediated vasodilat-
ing properties. In vitro studies have shown that
nebivolol dilates coronary resistance vessels in humans
through an agonist effect on endothelial b3-adrenor-
eceptors to release nitric oxide and promote neoangio-
genesis [19]. The nitric oxide-releasing and vasodilating
properties of nebivolol in coronary microvessels may
exert its beneficial effect in patients with ischemic and
dilated cardiomyopathies [20], particularly those with
diastolic dysfunction [21], given the direct lusitropic
properties of nitric oxide on the myocardium. Diseases
such as dyslipidemia, diabetes, and atherosclerosis are
all associated with a decrease in eNOS expression, nitric
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Fig. 5 Regression plot of collateral flow index versus heart rate
(top panel) and rate-pressure product (lower panel), respectively
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Fig. 4 Box plot of collateral flow index (CFI) at rest and after
intracoronary nebivolol in CAD patients. CFI decreased from
0.37T0.23 to 0.33T0.25, 0.28T0.3 (p<0.05), and 0.27T0.3 (p<0.05),
respectively, after 0.1, 0.25, and 0.5 mg of intracoronary
nebivolol
Table 5 Coronary resistance
Baseline Nebivolol 0.1 mg Nebivolol 0.25 mg Nebivolol 0.5 mg
Controls:
CR rest (mmHgsec/cm) 5.6T0.8 6.3T0.6 6.9T0.6 7.5T0.5*
CR hyperemic (mmHgsec/cm) 2.0T0.6 2.1T0.6 2.0T0.5 2.1T0.6
CRR 0.34T0.8 0.34T0.7 0.30T0.7** 0.29T0.6**
Coronary artery disease group:
CR rest (mmHgsec/cm) 4.6T1.7 4.8T2.1 4.3T1.9 4T1.4
CR hyperemic(mmHgsec/cm) 2.2T0.6 2.1T0.7 1.8T0.6* 1.7T0.4*
CRR 0.5T0.1 0.47T0.2 0.47T0.1 0.45T0.1
CR Coronary resistance; CRR coronary resistance ratio
*p<0.05; **p<0.01
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oxide bioavailability, or both, which could limit the
clinical impact of a drug that depends on nitric oxide
release. The marked vasodilating effect of nebivolol in
human coronary microvessels is well established under
in vitro conditions [13]. The present study compliments
a recent in vivo investigation by Galderisi et al. who
demonstrated improvement of coronary flow reserve
in hypertensive patients without coronary artery dis-
ease [22]. Nebivolol increased coronary flow reserve
through an increase in hyperemic flow without changing
resting flow comparable to our findings in the coronary
artery disease patients. However, the two studies differ
substantially. In the work by Galderisi: (1) exclusively
hypertensive subjects without coronary artery disease
were investigated, (2) coronary flow reserve was
assessed by non-invasive means (Doppler echocardiog-
raphy), and (3) nebivolol was administered by the oral
route over 4 weeks. Importantly, Galderisi was able to
demonstrate that adequate nebivolol concentrations
are reached in the coronary blood by conventional oral
administration in order to obtain relevant effects on
coronary flow. A comparable effect on the brachial
artery flow-mediated vasodilation was shown by Leka-
kis with an oral dose of 5 mg of nebivolol [23].
Differences in response to nebivolol between coronary
artery disease and control group
In controls, endothelial function is normal with a
normal coronary flow reserve value. In coronary artery
disease patients, endothelial dysfunction is present and
coronary flow reserve is reduced. Stimulation of the
endothelium by nebivolol acts mainly in the diseased
arteries with an increase in maximal coronary flow and
almost normalization of coronary flow reserve. In the
normal coronary artery, the beta-blocking effect of
nebivolol predominates rather than the vasodilating
effect on maximal flow. Thus, in the presence of normal
endothelial function, the beta-blocking effect of nebi-
volol becomes evident, whereas in the diseased vessel
the vasodilating effect of nebivolol prevails. These
changes are reflected by the changes in coronary pe-
ripheral resistance with an increase in resistance in the
controls at rest and a decreased resistance in coronary
artery disease patients under hyperemic conditions.
The anti-ischemic effect of nebivolol in the presence
of coronary artery disease is based on the following
mechanisms: (1) reduction in oxygen demand through
the b1-adrenoreceptor blocking properties as reflected
by the decrease in heart rate and rate-pressure product,
(2) maintained (not diminished) coronary flow at rest,
(3) increased coronary flow reserve through the
increase in hyperemic flow (=increased oxygen supply).
These three mechanisms influence the oxygen supply–
demand balance of the myocardium favorably.
Collateral flow index and nebivolol The coronary
collateral flow decreased significantly after nebivolol.
Previous reports have shown a similar response of
coronary collateral flow to the selective b1-blocker
metoprolol [24]. The reduction in coronary collateral
flow has been attributed to a vasoconstrictive response
of the collateral vessel to metoprolol with an increase
in vascular resistance. With nebivolol a similar re-
sponse was observed with a decrease in coronary
collateral perfusion. However, there was a close
relation between heart rate and changes in collateral
flow. This finding supports the hypothesis that collat-
eral flow is mainly determined by the requirements of
the collateral-dependent myocardium.
Limitations Several limitations have to be considered
for this study:
(1) Changes in heart rate and mean aortic pressure may
affect coronary flow and flow velocity. In controls,
baseline flow decreased after nebivolol administra-
tion, and the rise in coronary flow reserve was
attributed to the reduction in coronary flow at rest
in the presence of a maintained hyperemic flow. In
coronary artery disease patients, however, the de-
crease in heart rate and mean aortic pressure after
nebivolol was not associated with a change in resting
coronary flow. This finding could be explained by the
beneficial effect of nebivolol on nitric oxide-release
which may counteract the flow reduction induced by
the presence of endothelial dysfunction in coronary
artery disease patients.
(2) Comparisons with other selective b1-adrenoreceptor
antagonists (i.e., metoprolol) were not performed.
Previous studies from our group demonstrated a
similar response of coronary flow and reserve
capacity [12] as well as collateral flow [24] to
metoprolol. However, study protocols differ substan-
tially, and therefore, data may not be extrapolated
for comparison purposes.
(3) The control group consisted of patients who under-
went coronary angiography to exclude the presence
of coronary artery disease. Therefore, the results of
the control group do not reflect the response to
nebivolol in normals.
(4) There was an imbalance between the two groups with
regard to smoking and medication with ACE inhib-
itors. We therefore performed an multivariable
regression analysis with covariates to determine the
effect of medication and presence of risk factors
(smoking, diabetes) on the effect of nebivolol on
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coronary flow and flow reserve. The analysis of
variance showed no effect of cardiovascular risk
factors as well as baseline medication including
ACE-inhibitors on the results obtained.
(5) Coronary flow reserve may have been affected by
other factors apart form endothelial function such as
left ventricular mass and cholesterol values. Choles-
terol values were similar in the two study groups. Left
ventricular mass was not determined and thus no
comment on this relationship can be made, except
that the incidence of hypertension was similar in both
groups.
(6) The concomitant use of beta-blockers in the two
groups may have affected the results of the present
study. The only beta-blocker used was metoprolol
and in a similar percentage in both groups. However,
all cardiovascular medication was stopped at least 48
h prior to the study and all patients showed decrease
in heart rate under nebivolol.
Conclusions
Nebivolol is associated with a significant increase in
coronary flow reserve in controls as well as in
patients with coronary artery disease. In controls,
the rise in coronary flow reserve is mainly attributed
to the decrease in resting coronary flow (b-blocking
effect), whereas in coronary artery disease patients,
this effect is mainly due to an increase in maximal
coronary flow during adenosine infusion without a
change in resting flow. The increase in coronary flow
(supply j) and the reduction in rate-pressure product
(demand ,) after nebivolol explain the excellent
anti-ischemic properties of this compound in patients
with coronary artery disease. Coronary flow index
decreased with nebivolol parallel to the reduction in
oxygen requirements of the collateral-dependent
myocardium.
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